Xilio Development Stock Today
| XLO Stock | USD 0.59 0.02 2.48% |
PerformanceWeakest
| Odds Of DistressRisky
|
Xilio Development is selling at 0.59490001 as of the 31st of January 2026; that is 2.48 percent decrease since the beginning of the trading day. The stock's open price was 0.61. Xilio Development has a very high chance of experiencing financial distress in the next few years of operation. It has also generated negative returns for investors over the last 90 days. The performance scores are derived for the period starting the 2nd of November 2025 and ending today, the 31st of January 2026. Click here to learn more.
Business Domain Pharmaceuticals, Biotechnology & Life Sciences | IPO Date 22nd of October 2021 | Category Healthcare | Classification Health Care |
Xilio Therapeutics, Inc., a clinical-stage biotechnology company, develops immunotherapies to improve the immune system of cancer patients. Xilio Therapeutics, Inc. was founded in 2016 and is headquartered in Waltham, Massachusetts. Xilio Therapeutics operates under Biotechnology classification in the United States and is traded on NASDAQ Exchange. The company has 67.54 M outstanding shares of which 2.09 M shares are at this time shorted by investors with about 5.7 days to cover. More on Xilio Development
Moving together with Xilio Stock
| 0.81 | EVGN | Evogene | PairCorr |
| 0.68 | IMNN | Imunon Inc | PairCorr |
| 0.63 | IPHA | Innate Pharma | PairCorr |
| 0.8 | LYRA | Lyra Therapeutics | PairCorr |
| 0.84 | MBIO | Mustang Bio | PairCorr |
Moving against Xilio Stock
Follow Valuation Profit Patterns Odds of Bankruptcy
Check how we calculate scores
Xilio Stock Highlights
| CEO President | PharmD BCPS | |||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Business Concentration | Biotechnology, Pharmaceuticals, Biotechnology & Life Sciences, Health Care, NASDAQ Composite, Health Care, Biotechnology, Biotechnology, Healthcare (View all Sectors) | |||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Average Analyst Recommendation | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Financial Strength
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Debt LevelsXilio Development utilizes debt financing to potentially enhance returns on invested capital. The relationship between total debt and total assets provides valuable insight into Xilio Development's leverage profile, showing how much of Xilio Development's resources are funded through borrowing.
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Xilio Development (XLO) is traded on NASDAQ Exchange in USA and employs 64 people. Xilio Development is listed under Biotechnology category by Fama And French industry classification. The company currently falls under 'Micro-Cap' category with a total capitalization of 41.19 M. Xilio Development runs under Biotechnology sector within Health Care industry. The entity has 67.54 M outstanding shares of which 2.09 M shares are at this time shorted by investors with about 5.7 days to cover.
Xilio Development has about 159.41 M in cash with (18.38 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 5.82, which can makes it an attractive takeover target, given it will continue generating positive cash flow.
Check Xilio Development Probability Of Bankruptcy
Ownership AllocationXilio Development retains a total of 67.54 Million outstanding shares. Xilio Development owns significant amount of outstanding shares owned by insiders. An insider is usually defined as a CEO, other corporate executive, director, or institutional investor who own at least 10% of the company's outstanding shares. Please note that no matter how many assets the company shows, if the real value of the company is less than the current market value, you may not be able to make money on it.
Check Xilio Ownership Details
Xilio Stock Institutional Holders
| Instituion | Recorded On | Shares | |
| Squarepoint Ops Llc | 2025-06-30 | 235.5 K | |
| Balyasny Asset Management Llc | 2025-06-30 | 198.9 K | |
| Renaissance Technologies Corp | 2025-06-30 | 164.2 K | |
| Honkamp Krueger Financial Services Inc | 2025-06-30 | 142.3 K | |
| Two Sigma Investments Llc | 2025-06-30 | 78 K | |
| Northern Trust Corp | 2025-06-30 | 66.6 K | |
| Bridgeway Capital Management, Llc | 2025-06-30 | 56.1 K | |
| State Street Corp | 2025-06-30 | 43.4 K | |
| Xtx Topco Ltd | 2025-06-30 | 34.7 K | |
| Bain Capital Life Sciences Investors, Llc | 2025-06-30 | 4.6 M | |
| Merck & Co Inc | 2025-06-30 | 1.5 M |
Xilio Development Historical Income Statement
Xilio Stock Against Markets
Xilio Development Corporate Management
| Martin MD | Pres RD | Profile | |
| Scott Coleman | Chief Officer | Profile | |
| Uli Bialucha | Chief Officer | Profile | |
| Ruth Moulin | Senior Affairs | Profile | |
| Julissa Viana | Vice Communications | Profile | |
| Stacey Davis | Chief Officer | Profile | |
| Christopher Frankenfield | Chief Officer | Profile |
Already Invested in Xilio Development?
The danger of trading Xilio Development is mainly related to its market volatility and Company specific events. As an investor, you must understand the concept of risk-adjusted return before you start trading. The most common way to measure the risk of Xilio Development is by using the Sharpe ratio. The ratio expresses how much excess return you acquire for the extra volatility you endure for holding a more risker asset than Xilio Development. The Sharpe ratio is calculated by using standard deviation and excess return to determine reward per unit of risk. To understand how volatile Xilio Development is, you must compare it to a benchmark. Traditionally, the risk-free rate of return is the rate of return on the shortest-dated U.S. Treasury, such as a 3-year bond.
When determining whether Xilio Development offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of Xilio Development's financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Xilio Development Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Xilio Development Stock: Check out Your Current Watchlist to better understand how to build diversified portfolios, which includes a position in Xilio Development. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in board of governors. To learn how to invest in Xilio Stock, please use our How to Invest in Xilio Development guide.You can also try the Cryptocurrency Center module to build and monitor diversified portfolio of extremely risky digital assets and cryptocurrency.
Will Biotechnology sector continue expanding? Could Xilio diversify its offerings? Factors like these will boost the valuation of Xilio Development. Anticipated expansion of Xilio directly elevates investor willingness to pay premium valuations. Accurate valuation requires analyzing both current fundamentals and future growth trajectories. Every Xilio Development data point contributes insight, yet successful analysis hinges on identifying the most consequential variables.
Earnings Share (0.61) | Revenue Per Share | Quarterly Revenue Growth 7.425 | Return On Assets | Return On Equity |
The market value of Xilio Development is measured differently than its book value, which is the value of Xilio that is recorded on the company's balance sheet. Investors also form their own opinion of Xilio Development's value that differs from its market value or its book value, called intrinsic value, which is Xilio Development's true underlying value. Seasoned market participants apply comprehensive analytical frameworks to derive fundamental worth and identify mispriced opportunities. Because Xilio Development's market value can be influenced by many factors that don't directly affect Xilio Development's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Xilio Development's value and its price as these two are different measures arrived at by different means. Investors typically determine if Xilio Development is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. Meanwhile, Xilio Development's quoted price indicates the marketplace figure where supply meets demand through bilateral consent.